{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:10:24Z","timestamp":1790662224403,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ymgme.2017.08.004","type":"journal-article","created":{"date-parts":[[2017,8,19]],"date-time":"2017-08-19T03:32:28Z","timestamp":1503113548000},"page":"121-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["A simple method for quantification of plasma globotriaosylsphingosine: Utility for Fabry disease"],"prefix":"10.1016","volume":"122","author":[{"given":"Andrew","family":"Talbot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice M.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9092-8942","authenticated-orcid":false,"given":"Maria","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2017.08.004_bb0005","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3733","article-title":"\u03b1-Galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2001"},{"key":"10.1016\/j.ymgme.2017.08.004_bb0010","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF03401671","article-title":"Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes","volume":"3","author":"Eng","year":"1997","journal-title":"Mol. Med."},{"key":"10.1016\/j.ymgme.2017.08.004_bb0015","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","article-title":"Natural course of Fabry disease: changing pattern of causes of death in FOS outcome survey","volume":"46","author":"Mehta","year":"2009","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2017.08.004_bb0020","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/gim.2016.55","article-title":"Is it Fabry disease?","volume":"18","author":"Schiffmann","year":"2016","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2017.08.004_bb0025","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1373\/clinchem.2004.041418","article-title":"Urine metabolite profiling for the identification of Fabry hemizygotes and heterozygotes","volume":"51","author":"Fuller","year":"2005","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2017.08.004_bb0030","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/1873-3468.12104","article-title":"Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingolipid bases during deficiency of glycosidases","volume":"590","author":"Ferraz","year":"2016","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ymgme.2017.08.004_bb0035","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2017.08.004_bb0040","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","article-title":"Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease","volume":"52","author":"Smid","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2017.08.004_bb0045","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma lysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.08.004_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/7b2c04df-8592-4fb7-8608-3039db28b504","article-title":"Globotriaosylsphingosine accumulation and not alpha-galactosidase A deficiency causes endothelial dysfunction in Fabry disease","volume":"7","author":"Namdar","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2017.08.004_bb0055","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbadis.2010.05.003","article-title":"Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease","volume":"1802","author":"Rombach","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2017.08.004_bb0060","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/ndt\/gfq306","article-title":"Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy","volume":"26","author":"Sanchez-Ni\u00f1o","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2017.08.004_bb0065","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1373\/clinchem.2012.192138","article-title":"Quantification of globotriaosylsphingosine in plasma and urine of Fabry patients by stable isotope ultra performance liquid chromatography-tandem mass spectrometry","volume":"59","author":"Gold","year":"2013","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2017.08.004_bb0070","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cca.2013.09.008","article-title":"Plasma globotriaosylsphingosine (lyso) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A)","volume":"426","author":"Liao","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2017.08.004_bb0075","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ymgme.2012.07.003","article-title":"Mutant \u03b1-galactosidase A with M296I does not cause elevation of the plasma globotriaosylsphingosine level","volume":"104","author":"Mitobe","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.08.004_bb0080","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","article-title":"Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy","volume":"1812","author":"van Breeman","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2017.08.004_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057631","article-title":"Migalastat HCl reduces globotriaosylsphingosine (lysoGb3) in Fabry transgenic mice and in the plasma of Fabry patients","volume":"8","author":"Young-Gqamana","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymgme.2017.08.004_bb0090","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","volume":"18","author":"Lang","year":"2005","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"10.1016\/j.ymgme.2017.08.004_bb0095","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.cca.2015.06.003","article-title":"Variations in the GLA gene correlate with globotriaosylsphingosine analog levels in urine and plasma","volume":"447","author":"Ferreira","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2017.08.004_bb0100","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cca.2012.09.026","article-title":"LC-MS\/MS analysis of plasma lyso-Gb3 in Fabry disease","volume":"414","author":"Boutin","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgme.2017.08.004_bb0105","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ymgme.2014.11.004","article-title":"The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype. Data from individual patients and family studies","volume":"114","author":"Ferreira","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.08.004_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003632","article-title":"Functional characterisation of alpha-galactosidase A mutations as a basis for a new classification system in Fabry disease","volume":"9","author":"Lukas","year":"2013","journal-title":"PLoS Genet."},{"key":"10.1016\/j.ymgme.2017.08.004_bb9000","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","article-title":"Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease","volume":"7","author":"Niemann","year":"2014","journal-title":"Circ. Cardiovasc. Genet."},{"key":"10.1016\/j.ymgme.2017.08.004_bb9005","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cca.2017.01.018","article-title":"Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation","volume":"466","author":"Auray-Blais","year":"2017","journal-title":"Clin. Chim. Acta"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671921730402X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109671921730402X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T11:58:19Z","timestamp":1570017499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109671921730402X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":24,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S109671921730402X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2017.08.004","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A simple method for quantification of plasma globotriaosylsphingosine: Utility for Fabry disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2017.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}